We treated two HNSCC cell lines with 10 μg mL−1 squamocin or 25 μm (14 μg mL−1) EPZ‐6438, the first enzymatic inhibitor of EZH2 approved by the US Food and Drug Administration (FDA). The gene discussed is EZH2; the disease is head and neck squamous cell carcinoma.